GlassScriptPhysician profile
Michael Thomas Monroe
NPI 1447383385
$4,009.85
in general payments reported to CMS, 2019-2025
21 companies · $89.39 in 2025
The $89.39 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $897 · 2024: $3,024 · 2025: $89.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,950 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,949.86 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,040.00 | 2023-2024 | |
| Amgen INC. | $585.05 | 2023-2025 | Enbrel, Otezla, Krystexxa |
| Mallinckrodt Hospital Products INC. | $444.52 | 2023-2024 | Acthar |
| Astrazeneca Pharmaceuticals LP | $266.51 | 2023-2024 | Saphnelo |
| Pfizer INC. | $261.42 | 2023-2025 | |
| Janssen Biotech, INC. | $243.76 | 2023-2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $196.53 | 2023-2024 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.24 | 2023-2024 | Cyltezo |
| Fresenius Kabi USA, LLC | $140.82 | 2023-2024 | Idacio |
| Azurity Pharmaceuticals, INC. | $124.37 | 2023-2025 | Horizant, Horizant |
| Organon LLC | $119.59 | 2023-2024 | Hadlima, Renflexis |
| Ani Pharmaceuticals, INC. | $97.02 | 2023-2024 | Purified Cortrophin Gel |
| Ucb, INC. | $67.71 | 2023-2024 | Cimzia, Bimzelx |
| Scilex Pharmaceuticals INC. | $49.04 | 2024 | |
| Lilly USA, LLC | $46.00 | 2024 | Taltz |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alvogen INC | $36.50 | 2024 | Teriparatide |
| Takeda Pharmaceuticals U.S.A., INC. | $32.94 | 2024 | Hyqvia |
| Genzyme Corporation | $20.96 | 2023 | |
| Horizon Therapeutics Plc | $20.54 | 2023 | Krystexxa |
| Fidia Pharma USA INC. | $19.40 | 2024 | Triluron, Hymovis, Hyalgan |
| Kyowa Kirin, INC. | $17.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Monroe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.